Home > Insider Trading > Filing (0000899243-20-005685)

Filing Details

Accession Number:: 0000899243-20-005685
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-02-24 21:01:00
Reporting Period:: 2020-02-20

Accepted Time:: 2020-02-24 21:01:00
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
896262	Amedisys Inc	AMED	Services-Home Health Care Services (8082)	113131700

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1689925	Paul Michael North	3854 American Way, Suite A Baton Rouge LA 70816	Chief Information Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2020-02-20	130	$194.12	9,420	No	4	F	Direct
Common Stock	Acquisiton	2020-02-21	5,625	$32.56	15,045	No	4	M	Direct
Common Stock	Disposition	2020-02-21	600	$192.86	14,445	No	4	S	Direct
Common Stock	Disposition	2020-02-21	3,435	$193.87	11,010	No	4	S	Direct
Common Stock	Disposition	2020-02-21	1,590	$194.62	9,420	No	4	S	Direct
Common Stock	Acquisiton	2020-02-21	3,788	$46.35	13,208	No	4	M	Direct
Common Stock	Disposition	2020-02-21	441	$192.84	12,767	No	4	S	Direct
Common Stock	Disposition	2020-02-21	2,000	$193.84	10,767	No	4	S	Direct
Common Stock	Disposition	2020-02-21	1,347	$194.57	9,420	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	F	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2020-02-21	5,625	$0.00	5,625	$32.56
Common Stock	Stock Option (right to buy)	Disposition	2020-02-21	3,788	$0.00	3,788	$46.35

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	2019-06-02	2025-06-02	No	4	M	Direct
1,894	2018-01-20	2027-01-20	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	457	Indirect	Through 401(k) Plan

Footnotes

The total amount of shares beneficially owned includes 1,027 shares held in an employee stock purchase plan account.
These sales were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.40 to $193.32, inclusive. The reporting person undertakes to provide to Amedisys, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.40 to $194.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.40 to $195.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $192.27 to $193.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $193.29 to $194.26, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (7) to this Form 4.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.27 to $195.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (8) to this Form 4.
The information in this report is based on a plan statement dated as of December 31, 2019.
On January 20, 2017, the reporting person was granted an option to purchase 7,577 shares of common stock. The options are subject to time-based vesting conditions. 1,895 of the options vested on January 20, 2018, 1,894 of the options vested on January 20, 2019, 1,894 of the options vested on January 20, 2020, and 1,894 of the options will vest on January 20, 2021, provided that the reporting person remains continuously employed by the Issuer on such date, subject to prorated vesting provisions as provided in the award agreement for the stock options. The reporting person previously exercised 1,895 of the options.